Packaging Coordinators
Packaging Coordinators is recorded as a service provider in 12 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 12 of 12 trials · Latest update first
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects with Classic Congenital Adrenal Hyperplasia
Sponsor Spruce Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available6 trial-level findings · Read insights
- The planned number of investigative sites was increased from 40 to 55.
- Weekly waking saliva collection was removed because of practical feasibility challenges and to reduce participant burden.
- Scheduled telephone contacts were reduced to lessen participant burden, while targeted as-needed contacts were retained or added for dose escalation, glucocorticoid tapering, safety monitoring, and compliance follow-up.
- COVID-19 mitigation measures allowed remote study visits and screening by telemedicine or at the participant's home where locally approved.
- Screening information collected within 45 days before Day 1 could be used when necessary, and screening data from the parallel SPR001-204 study could be transferred for eligibility determination.
- Eligibility criteria were revised to remove the elevated ACTH requirement, expand the acceptable glucocorticoid replacement range to 15-60 mg/day hydrocortisone equivalent, and update diagnostic and A4 requirements.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 2a, double-blind, placebo-controlled, multi-center, randomized study evaluating LSTA1 when added to standard of care (SoC) versus standard of care alone in subjects with advanced solid tumors (BOLSTER)
Sponsor Lisata Therapeutics Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
Operational learnings available1 trial-level finding · Read insights
- The study was terminated in Spain before any patients were enrolled.
These findings describe the trial, not the service provider’s performance or responsibility.
(Peak) A Phase 3 Randomized, Open-label, Multicenter Clinical Study of CGT9486+Sunitinib vs Sunitinib in Subjects with Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors
Sponsor Cogent Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Axatilimab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)
Sponsor Syndax Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
Sponsor Avidity Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (delpacibart zotadirsen) for the Treatment of DMD with Gene Mutations Amenable to Exon 44 Skipping
Sponsor Avidity Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects with Classic Congenital Adrenal Hyperplasia
Sponsor Spruce Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous AOC 1001 for the Treatment of Myotonic Dystrophy Type 1
Sponsor Avidity Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of NIDO-361 in Patients with Spinal and Bulbar Muscular Atrophy (SBMA)
Sponsor Nido Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous NVG-2089 in Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Sponsor Nuvig Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
An Open-Label, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous NVG-2089 in Participants with Immune Thrombocytopenia
Sponsor Nuvig Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1b/2a Open-label Single Ascending Doses (SAD) and Multiple Ascending Doses (MAD) Research Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Participants with AATD Pi*ZZ on WVE-006 (RestorAATion-2)
Sponsor Wave Life Sciences Ireland Limited
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Packaging Coordinators?
The 2026-10-09 snapshot links Packaging Coordinators to 12 distinct CTIS trials. Recorded services include Medicinal product management, Drug Depot Services. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Packaging Coordinators?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Endocrinology, Gastroenterology, Genetic and Congenital Disorders. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Packaging Coordinators conducted?
The linked trials record locations in 20 countries, including Spain, Italy, Germany, Poland, Denmark. These are trial locations, not confirmed office locations or countries where Packaging Coordinators delivered services.
What can this page tell me about Packaging Coordinators's trial experience?
Browse 12 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 2 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Packaging Coordinators. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Packaging Coordinators LLC